TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: FEV1 decline from baseline to treatment end
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: sputum bacterial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Decreases in IGF‐I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Decreases in IGFBP‐3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Primary endpoint achievement
Endpoint domain: Mortality/survival
Primary endpoint: Target lesion revascularisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 5% halothane inductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pullout force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Relative rotation at the bone‐screw interface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean ASES score of the affected shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of chronic airways obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Confirmed hypoglycemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Events consistent with urinary tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Events consistent with genital infection
Endpoint domain: Adverse events/effects
Primary endpoint: Average daily CSF drainage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: IVH volume over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma total cobalamin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma haptocorrin bound cobalamin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximal IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MRI evidence of synovitis and erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Assessment Questionnaire (HAQ) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean area under the plasma concentration‐time curve (AUC(0‐33)) of celiprolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration values of celiprolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative excretion into urine of celiprolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 3/4 sensory neuropathy incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of strokes and systemic emboli
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of major and CRNM bleeds
Endpoint domain: Adverse events/effects
Primary endpoint: meal fat storage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: systemic lipolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: meal fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 10-year mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: rate of decline in fear of bodily sensations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of acute respiratory distress syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: significant depressive symptom deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individualized rehabilitation programme effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Overall KAP score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Daytime sleepiness improvement
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mood state improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Eradication rates of moxifloxacin sensitive/resistant strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in HAM-A total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum prealbumin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum albumin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean metered phacoemulsification time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean ultrasound power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Loss of corneal endothelial cell density (ECD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: 3-dose coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Public support for legislation to prohibit weight-based discrimination
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of fistula output at 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to fistula closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean discomfort scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Significant transient discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Segmental distention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: postintervention maximal walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiplatelet effect measured by VASP assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Antiplatelet effect measured by Multiplate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SS testing cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SR test improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: participant mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sweep VEP acuity at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: self assessment of mouth dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self assessment of speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self assessment of swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SGRQ-I symptom domain scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hamstring-quadriceps balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Blood sugar concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum interleukin‐6 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite VFQ-25 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerability of the combination of cyclosporin and tezosentan
Endpoint domain: Adverse events/effects
Primary endpoint: Viral load below 20 copies/ml at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peak mean increase in CD4 cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression rates to study endpoints within 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Pulse rate per respiration (P/R ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subendocardial viability ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal ureteral access sheath insertion force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of grade 2 or greater ureteral injury
Endpoint domain: Adverse events/effects
Primary endpoint: Days of analgesic use
Endpoint domain: Adverse events/effects
Primary endpoint: Latency of saccade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Appearance rate of predictive saccades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Left ventricular end‐diastolic diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: grade 2 and higher gastrointestinal complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: grade 2 and higher genitourinary injury rate
Endpoint domain: Adverse events/effects
Primary endpoint: Constant and UCLA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genomic expression variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of penetration in dentin and cementum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision of height measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of the dawn phenomenon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: night-time glycaemic variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of malignant ventricular arrhythmias (VAs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: NGAL levels in identifying CIN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: change in mean minimal lumen diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: degree of chest pain perception
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood Pressure Control Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PDR of urea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PDR of phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of pyuria, bacteriuria or febrile infection
Endpoint domain: Adverse events/effects
Primary endpoint: Soft tissue stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental Health-Related Quality of Life (HRQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Return to prefracture ambulation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of femoral fractures
Endpoint domain: Adverse events/effects
Primary endpoint: HOMA index for insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of high-risk individuals with cholesterol > 7 mmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean LDL-C levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum concentrations of iron, ionized calcium, and inorganic phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Thyroid hormone levels (free tri‐iodothyronine, free thyroxine, thyroid‐stimulating hormone)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Recovery rate from irritant contact dermatitis (ICD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MIP-1alpha expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Knodell score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinol level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4HPR plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of BPAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing rate of acute duodenal ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of pain free ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of H. pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intention to seek help
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percentage of sensor glucose in range (TIR 70‐180 mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achieving three or more SCBMs per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient rating of constipation treatment effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in PAC-QOL satisfaction subscale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: problems falling asleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: degree of conversion (DC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lines of vision lost at sixth month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phase II time constant of V̇O2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficulties conceiving
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Preference for treatment in ECOG 4 patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Comfort level discussing death and dying
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sense of failure with disease progression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: overall drainage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean scores for Consonant Nucleus Consonant words
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing in Noise Test (HINT) sentences in quiet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing in Noise Test (HINT) sentences in noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal reduction in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Kilocalories intake from snacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mortality from methicillin-resistant Staphylococcus aureus (MRSA) pneumonia
Endpoint domain: Mortality/survival
Primary endpoint: Emergence of multidrug-resistant organisms (MRSA)
Endpoint domain: Adverse events/effects
Primary endpoint: Average lateral opening of the upper ankle joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EFP appearance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Choroidal thickness at the fovea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum of injuries to the ankle, knee, hamstring, and groin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence or absence of cervical-vaginal organisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Refractive prediction error
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Internal MTF values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of relapse of diverticular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Geometric mean concentration of antibody to hepatitis B surface antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rates of seroprotection to HepB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of early hepatic encephalopathy (HE) after TIPS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median duration of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median period of postoperative discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time for tissue condition to normalize
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of oxycodone administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor markers reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Days of drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom reduction in OCD and comorbid depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Y-BOCS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: safety and effectiveness of EMDR therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median oral cGVHD examination score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median self‐rated oral pain severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abstinence rates at 15 month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual tumor presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Caspase-3 staining levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Barthel Index Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Choroid thickness measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver agreement on lumbar MRI findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cardiovascular side-effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Executive functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: survival analysis of groups
Endpoint domain: Mortality/survival
Primary endpoint: clinical parameters scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual medical costs reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: crisis services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: annual total health care costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ciprofloxacin AUC(infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ciprofloxacin maximum plasma concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to ciprofloxacin C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Debonded crowns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractured crowns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AHt (Adult Height)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gain-in-height SDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-lactulose symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sao2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: IRIS events occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Resolution time of IRIS events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality due to CNS TB-IRIS
Endpoint domain: Mortality/survival
Primary endpoint: RET‐Y levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity in detecting hemodynamically relevant RAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity in detecting hemodynamically relevant RAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes